ASCO 2022 on KEYNOTE-651: Pembrolizumab + mFOLFOX7/FOLFIRI for mCRC: Long-Term Follow-Up of Cohorts B and D

2,338 views
June 9, 2022
0 Comments
Login to view comments. Click here to Login